-
公开(公告)号：US20240102915A1
公开(公告)日：2024-03-28
申请号：US17766562
申请日：2020-10-06
IPC分类号： G01N15/14 , B01L3/00 , G01N15/10 , G01N33/487
CPC分类号： G01N15/1484 , B01L3/502761 , G01N15/1031 , G01N33/48728 , B01L2200/0663 , B01L2300/0645 , G01N2015/1006 , G01N2015/1495
摘要： The invention relates to a measuring device (10) for measuring physical characteristics of cells. The device (10) comprises: a microfluidic chip (20) provided with a flow channel (22) for allowing cells to flow through; a manipulator (24) configured to apply deformation force to a cell in a continuous flow; and a sensor (26) configured to sense a physical characteristic of the cell. The manipulator (24) and the sensor (26) are configured to define a width (W2) of the flow channel (22) as a gap formed between them. The manipulator (24) is configured to apply the deformation force to the cell by compressing the cell against the sensor (26).
-
公开(公告)号：US20230002497A1
公开(公告)日：2023-01-05
申请号：US17638464
申请日：2020-09-03
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÈ ET DE LA RECHERCH MÉDICALE , Centre National de la Recherche Scientifque (CNRS) , Université de Lille , Institut Pasteur de Lille , Université de Montpellier , INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER
发明人： Philippe GOSSET , Muriel PICHAVANT , Pierre MARTINEAU , Myriam CHENTOUF , Bruno ROBERT , Mélina LE ROUX
摘要： Chronic obstructive pulmonary disease (COPD) remains a major cause of morbidity and mortality worldwide. Acute exacerbation of COPD (AE-COPD) in patients are mostly due to respiratory infection and are associated with an inexorable decline in lung function, enhanced oedema as well as airway and systemic inflammation. Previous results show that treatment with anti-IL-20Rb blocking antibodies increased the bacterial clearance in control mice infected by S. pneumoniae and protected CS-exposed mice from bacterial infection, by decreasing the bacterial burden and the inflammatory infiltrate. Therefore there is an interest for generating monoclonal antibodies specific for IL-20Rb with a neutralizing activity for their use in the treatment of AE-COPD. The present invention fulfills this need by providing antibodies having specificity for IL-20Rb.
-
3.发明申请公开(公告)号：US20210177814A1
公开(公告)日：2021-06-17
申请号：US17053817
申请日：2018-05-09
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Université d'Aix Marseille , Centre National de la Recherche Scientifque (CNRS)
发明人： Jessica PEREGO , Philippe PIERRE , Evelina GATTI
IPC分类号： A61K31/44 , A61K31/40 , A61K31/155 , A61P31/14
摘要： The present invention relates to the use of Guanabenz or derivates thereof for the treatment of type I IFN-dependent pathologies. The inventors investigate here how pharmacological interference with the eIF2α-P pathway can be beneficial for the treatment of immune pathological conditions. Using both mouse and human DCs, as well as B cells, they show that GBZ prevents endosomal toll-like-receptor 9 (TLR9) activation by CpG ODN or DNA-Immunoglobulin complexes, as well as TLR3, TLR7 and RIG-I like receptors (RLR, RIG-I or MDA5), by RNAs or small compounds. In vivo, GBZ treatment protects mice from CpG-dependent cytokine shock and decreases anti-nucleic acid auto-antibodies production in the TMPD-induced systemic lupus erythematosus model. The present invention thus relates to a method of treating a type I IFN-dependent pathology in a subject comprising administering the subject with Guanabenz or a derivative thereof.
-
公开(公告)号：US20210277155A1
公开(公告)日：2021-09-09
申请号：US16330645
申请日：2017-09-07
发明人： Alexandre Welle , Aurélien Vantomme , Jean-François Carpentier , Gilles Schnee , Olivier Miserque , Evgueni Kirillov
IPC分类号： C08F10/06 , C08F2/02 , C08F4/659 , C08F4/6592
摘要： The present invention relates to a new process for preparing a polypropylene using new bis(metallocene) compounds in catalyst compositions. The bis(metallocene) compounds of the invention are homo- or hetero bis(metallocene) molecules in which same or different metallocene moieties are connected by a phenylene bridge. The phenylene bridge is either para-substituted, meta-substituted or ortho-substituted by the two metallocene moieties
-
5.发明申请公开(公告)号：US20150246095A1
公开(公告)日：2015-09-03
申请号：US14430405
申请日：2013-10-01
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , INSTITUT PASTEUR DE LILLE , UNIVERSITE DE LILLE I-SCIENCES ET TECHNOLOGIES , UNIVERSITE DU DROIT ET DE LA SANTE LILLE 2 , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE (CNRS)
CPC分类号： A61K38/20 , A61K38/2066 , A61K45/06 , C12Q1/6883 , C12Q2600/118 , C12Q2600/156 , C12Q2600/158 , G01N33/6869 , G01N2800/26 , G01N2800/50 , A61K2300/00
摘要： The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza. In particular, the present invention relates to an interleukin 22 (IL-22) polypeptide for use in the prophylactic treatment of bacterial superinfections post-influenza in a subject in need thereof.
摘要翻译： 本发明涉及用于预防性治疗流感后细菌超感染的方法和药物组合物。 特别地，本发明涉及用于在有需要的受试者中预防性治疗流感后细菌超感染的白细胞介素22（IL-22）多肽。
-
公开(公告)号：US20230066065A1
公开(公告)日：2023-03-02
申请号：US17797265
申请日：2021-02-04
申请人： Institut National de la Santé et de la Recherche Médicale (INSERM) , Assistance Publique-Hôpitaux de Paris (APHP) , Centre National de la Recherche Scientifque (CNRS) , Fondation Imagine , Université Paris Cité
发明人： Pascale DE LONLAY-DEBENEY , Peter VAN ENDERT , Sebastian MONTEALEGRE , Caroline TUCHMANN-DURAND , Laure CACCAVELLI , Marine MADRANGE , Perrine RENARD
IPC分类号： A61K31/4706 , A61P3/00
摘要： Lipin-1 deficiency is a rare, life-threatening condition that causes severe rhabdomyolysis episodes (RM) triggered by febrile illness and effort. Now, the inventors treated 10 patients with LPIN1 mutations with hydroxychloroquine (HCQ) in an off open-label use phases 1 and 2 study, to assess safety, clinical, and biological effects of the drug. A first inclusion group of patients were treated with oral HCQ at a dose of 6.5 mg/Kg/day in one intake, not exceeding 400 mg/day. Five patients have not presented any new acute RM under treatment, except for 2 patients experimented one and two episodes of RM respectively despite HCQ in a context of gastroenteritis. Plasma levels of HCQ were in the range of 400 ng/ml except in the two patients who experimented RM, in whom the plasma HCQ levels were higher (1000 ng/ml). With a therapeutic adjustment, in order to maintain plasma levels of HCQ under 700 ng/ml, in a new group of patients, two patients did not suffer from new acute RM under treatment. HCQ had not seem to have benefit effect for one patient. Thus, the inventors describe the first human experience with HCQ for Lipin-1 disease. The results allow the inventors to propose low doses of HCQ as a long-term treatment to prevent further relapses in this severe disease.
-
公开(公告)号：US20180360877A1
公开(公告)日：2018-12-20
申请号：US16060721
申请日：2016-12-08
申请人： INSERM (Institut National de la Sante et de la Recherche Medicale) , Universite d'Aix Marseille , Centre National de la Recherche Scientifque (CNRS) , Max Delbruck Center for Molecular Medicine (MDC)
摘要： The present invention relates to methods for expanding a population of alveolar macrophages in a long term culture. In particular, an object of the present invention relates to a method of expanding a population of alveolar macrophages in a long term culture comprising culturing the population of alveolar macrophages in a culture medium supplemented with an amount of GM-CSF.
-
8.发明申请公开(公告)号：US20140370029A1
公开(公告)日：2014-12-18
申请号：US14360311
申请日：2012-11-23
申请人： Integragen , Institut National de la Sante et de la Recherche Medicale (INSERM) , Centre National de la Recherche Scientifque (CNRS) , Assistance Publique - Hopitaux de Paris , Universite Paris Descartes
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Q2600/178
摘要： The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level hsa-miR-31-3p miRNA in a sample of said patient. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor.
摘要翻译： 本发明涉及一种预测癌症患者是否可能对表皮生长因子受体（EGFR）抑制剂作出反应的方法，该方法包括测定所述癌细胞样品中hsa-miR-31-3p miRNA的表达水平 患者。 本发明还涉及预测对所述EGFR抑制剂作出反应的患者中EGFR抑制剂的治疗用途。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.019 秒)
